Hsbc Holdings PLC Buys Shares of 125,482 Xencor, Inc. $XNCR

Hsbc Holdings PLC acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 125,482 shares of the biopharmaceutical company’s stock, valued at approximately $2,083,000. Hsbc Holdings PLC owned 0.17% of Xencor as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in XNCR. AQR Capital Management LLC bought a new position in shares of Xencor during the first quarter worth $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Xencor by 9.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock valued at $471,000 after buying an additional 3,692 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Xencor by 89.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock valued at $7,732,000 after buying an additional 344,088 shares in the last quarter. Creative Planning lifted its holdings in Xencor by 25.3% during the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 3,661 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Xencor by 170.9% during the second quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company’s stock worth $2,594,000 after acquiring an additional 208,182 shares in the last quarter.

Xencor Price Performance

Xencor stock opened at $26.06 on Monday. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -12.01 and a beta of 0.85. The firm has a 50-day moving average of $19.80 and a 200-day moving average of $14.79. Xencor, Inc. has a one year low of $7.83 and a one year high of $30.61.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.51. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The business had revenue of $51.22 million for the quarter, compared to the consensus estimate of $18.89 million. During the same quarter in the previous year, the business earned ($0.41) earnings per share. Xencor’s quarterly revenue was up 17.4% on a year-over-year basis. As a group, sell-side analysts expect that Xencor, Inc. will post -3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on XNCR shares. Wedbush increased their price target on Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Wall Street Zen raised Xencor from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Royal Bank Of Canada raised their target price on shares of Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price target on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a report on Wednesday, June 24th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Xencor presently has an average rating of “Hold” and an average price target of $24.86.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.